Alexander G Duarte1, Shibu Thomas2, Zeenat Safdar3, Fernando Torres4, Luis D Pacheco5, Jeremy Feldman6, Bennet deBoisblanc7. 1. Division of Pulmonary/Critical Care Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX. Electronic address: aduarte@utmb.edu. 2. Division of Pulmonary/Critical Care Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX. 3. Pulmonary/Critical Care Medicine, Baylor College of Medicine, Houston, TX. 4. Pulmonary/Critical Care Medicine, The University of Texas Southwestern Medical Center, Dallas, TX. 5. Department of Obstetrics and Gynecology and Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, TX. 6. Arizona Pulmonary Specialists Ltd, Phoenix, AZ. 7. Pulmonary and Critical Care Medicine, LSU Health New Orleans, New Orleans, LA.
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease with a predilection for young women that is associated with right ventricular failure and premature death. PAH can complicate pregnancy with hemodynamic instability or sudden death during parturition and postpartum. Our aim was to examine the impact of PAH on pregnancy outcomes in the modern era. METHODS: We conducted a retrospective evaluation of pregnant patients with PAH managed between 1999 and 2009 at five US medical centers. Patient demographics, medical therapies, hemodynamic measurements, manner of delivery, anesthetic administration, and outcomes were assessed. RESULTS: Among 18 patients with PAH, 12 continued pregnancy and six underwent pregnancy termination. Right ventricular systolic pressure in patients managed to parturition was 82 ± 5 mm Hg and in patients with pregnancy termination was 90 ± 16 mm Hg. Six patients underwent pregnancy termination at mean gestational age of 13 ± 1.0 weeks with no maternal deaths or complications. Twelve patients elected to continue their pregnancy and were hospitalized at 29 ± 1.4 weeks. PAH-specific therapy was administered to nine (75%) at time of delivery consisting of sildenafil, IV prostanoids, or combination therapy. All parturients underwent Cesarean section at 34 weeks with one in-hospital death and one additional death 2 months postpartum for maternal mortality of 16.7%. CONCLUSIONS: Compared with earlier reports, maternal morbidity and mortality among pregnant women with PAH was reduced, yet maternal complications remain significant and patients should continue to be counseled to avoid pregnancy.
BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare disease with a predilection for young women that is associated with right ventricular failure and premature death. PAH can complicate pregnancy with hemodynamic instability or sudden death during parturition and postpartum. Our aim was to examine the impact of PAH on pregnancy outcomes in the modern era. METHODS: We conducted a retrospective evaluation of pregnant patients with PAH managed between 1999 and 2009 at five US medical centers. Patient demographics, medical therapies, hemodynamic measurements, manner of delivery, anesthetic administration, and outcomes were assessed. RESULTS: Among 18 patients with PAH, 12 continued pregnancy and six underwent pregnancy termination. Right ventricular systolic pressure in patients managed to parturition was 82 ± 5 mm Hg and in patients with pregnancy termination was 90 ± 16 mm Hg. Six patients underwent pregnancy termination at mean gestational age of 13 ± 1.0 weeks with no maternal deaths or complications. Twelve patients elected to continue their pregnancy and were hospitalized at 29 ± 1.4 weeks. PAH-specific therapy was administered to nine (75%) at time of delivery consisting of sildenafil, IV prostanoids, or combination therapy. All parturients underwent Cesarean section at 34 weeks with one in-hospital death and one additional death 2 months postpartum for maternal mortality of 16.7%. CONCLUSIONS: Compared with earlier reports, maternal morbidity and mortality among pregnant women with PAH was reduced, yet maternal complications remain significant and patients should continue to be counseled to avoid pregnancy.
Authors: D G Kiely; R Condliffe; V Webster; G H Mills; I Wrench; S V Gandhi; K Selby; I J Armstrong; L Martin; E S Howarth; F A Bu'lock; P Stewart; C A Elliot Journal: BJOG Date: 2010-04 Impact factor: 6.531
Authors: Adaani E Frost; David B Badesch; Robyn J Barst; Raymond L Benza; C Gregory Elliott; Harrison W Farber; Abby Krichman; Theodore G Liou; Gary E Raskob; Prieya Wason; Kathleen Feldkircher; Michelle Turner; Michael D McGoon Journal: Chest Date: 2010-06-17 Impact factor: 9.410
Authors: Cuoghi Edens; Bruna Costa Rodrigues; Marcela Ignacchiti Lacerda; Flavia Cunha Dos Santos; Guilherme R De Jesús; Nilson Ramires De Jesús; Roger A Levy; Cianna Leatherwood; Jess Mandel; Bonnie Bermas Journal: Rheumatology (Oxford) Date: 2018-07-01 Impact factor: 7.580
Authors: Kathryn J Lindley; C Noel Bairey Merz; Anita W Asgar; Natalie A Bello; Sonal Chandra; Melinda B Davis; Mardi Gomberg-Maitland; Martha Gulati; Lisa M Hollier; Eric V Krieger; Ki Park; Candice Silversides; Natasha K Wolfe; Carl J Pepine Journal: J Am Coll Cardiol Date: 2021-04-13 Impact factor: 24.094
Authors: Anna R Hemnes; David G Kiely; Barbara A Cockrill; Zeenat Safdar; Victoria J Wilson; Manal Al Hazmi; Ioana R Preston; Mandy R MacLean; Tim Lahm Journal: Pulm Circ Date: 2015-09 Impact factor: 3.017